Tixagevimab/cilgavimab for preventing COVID-19 during the Omicron surge: retrospective analysis of National Veterans Health Administration electronic data

Little is known regarding the effectiveness of tixagevimab/cilgavimab in preventing SARS-CoV-2 infection in vaccinated immunocompromised patients, particularly after the emergence of the Omicron variant. In this retrospective cohort study with exact matching and propensity score adjustment within th...

Descripción completa

Detalles Bibliográficos
Autores principales: Young-Xu, Yinong, Epstein, Lauren, Marconi, Vincent C., Davey, Victoria, Korves, Caroline, Zwain, Gabrielle, Smith, Jeremy, Cunningham, Fran, Bonomo, Robert A., Ginde, Adit A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10470809/
https://www.ncbi.nlm.nih.gov/pubmed/37535398
http://dx.doi.org/10.1128/mbio.01024-23

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10470809/
https://www.ncbi.nlm.nih.gov/pubmed/37535398
http://dx.doi.org/10.1128/mbio.01024-23

Ejemplares similares